December 2020 at a glance: focus on COVID-19, comorbidities and palliative care.
作者信息
Tomasoni Daniela, Adamo Marianna, Metra Marco
机构信息
Cardiac Catheterization Laboratory and Cardiology, Cardio-thoracic Department, Civil Hospitals; Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
出版信息
Eur J Heart Fail. 2020 Dec;22(12):2173-2174. doi: 10.1002/ejhf.1527.
Abstract
摘要
相似文献
1
December 2020 at a glance: focus on COVID-19, comorbidities and palliative care.2020年12月概览：聚焦于2019冠状病毒病、合并症与姑息治疗。
Eur J Heart Fail. 2020 Dec;22(12):2173-2174. doi: 10.1002/ejhf.1527.
2
June 2020 at a glance: focus on COVID-19, quality of life and comorbidities.2020年6月概览：聚焦于2019冠状病毒病、生活质量与合并症。
Eur J Heart Fail. 2020 Jun;22(6):917-918. doi: 10.1002/ejhf.1515.
3
March 2021 at a glance: focus on epidemiology, prevention and COVID-19.2021年3月概览：聚焦流行病学、预防与新型冠状病毒肺炎
Eur J Heart Fail. 2021 Mar;23(3):347-349. doi: 10.1002/ejhf.1878.
4
Frailty and SARS-CoV-2 infection. A population-based study in a highly endemic village.衰弱与新型冠状病毒感染。一项在高流行村庄开展的基于人群的研究。
J Neurol Sci. 2020 Nov 15;418:117136. doi: 10.1016/j.jns.2020.117136. Epub 2020 Sep 10.
5
The Palliative Performance Scale predicts mortality in hospitalized patients with COVID-19.舒缓治疗表现量表可预测 COVID-19 住院患者的死亡率。
Palliat Med. 2020 Oct;34(9):1228-1234. doi: 10.1177/0269216320940566. Epub 2020 Jul 17.
6
Frailty in the face of COVID-19.面对新冠疫情时的虚弱状态。
Age Ageing. 2020 Jul 1;49(4):499-500. doi: 10.1093/ageing/afaa095.
7
Age, comorbidity, frailty status: effects on disposition and resource allocation during the COVID-19 pandemic.年龄、合并症、虚弱状态：对新冠疫情期间处置方式和资源分配的影响
Swiss Med Wkly. 2020 Apr 30;150:w20269. doi: 10.4414/smw.2020.20269. eCollection 2020 Apr 20.
8
Perspectives on COVID-19 and palliative care research.关于新冠病毒病与姑息治疗研究的观点
Palliat Med. 2021 Jan;35(1):4-5. doi: 10.1177/0269216320983949.
9
A meta-analysis of comorbidities in COVID-19: Which diseases increase the susceptibility of SARS-CoV-2 infection?一项关于 COVID-19 合并症的荟萃分析：哪些疾病会增加 SARS-CoV-2 感染的易感性？
Comput Biol Med. 2021 Mar;130:104219. doi: 10.1016/j.compbiomed.2021.104219. Epub 2021 Jan 16.
10
After COVID-19: The Way We Die from Now On.后疫情时代：我们的死亡方式将从此改变。
Camb Q Healthc Ethics. 2021 Jan;30(1):69-72. doi: 10.1017/S0963180120000572.
本文引用的文献
1
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID-19. Results of the Cardio-COVID-Italy multicentre study.心力衰竭对因 COVID-19 住院患者的临床病程和结局的影响。意大利 Cardio-COVID 多中心研究的结果。
Eur J Heart Fail. 2020 Dec;22(12):2238-2247. doi: 10.1002/ejhf.2052. Epub 2020 Nov 27.
2
Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care: A joint position statement from the Heart Failure Association (HFA), European Heart Rhythm Association (EHRA), and European Association of Cardiovascular Imaging (EACVI) of the European Society of Cardiology.心脏再同步治疗的优化实施：呼吁采取行动以转诊和优化治疗：心力衰竭协会（HFA）、欧洲心律协会（EHRA）和欧洲心脏病学会的心血管影像协会（EACVI）的联合立场声明。
Eur J Heart Fail. 2020 Dec;22(12):2349-2369. doi: 10.1002/ejhf.2046.
3
In-hospital care in acute heart failure during the COVID-19 pandemic: insights from the German-wide Helios hospital network.COVID-19 大流行期间急性心力衰竭的院内治疗：来自德国 Helios 医院网络的见解。
Eur J Heart Fail. 2020 Dec;22(12):2190-2201. doi: 10.1002/ejhf.2044. Epub 2020 Dec 2.
4
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).癌症和心力衰竭的常见机制途径。代表欧洲心脏病学会（ESC）心力衰竭协会（HFA）转化研究委员会的科学路线图。
Eur J Heart Fail. 2020 Dec;22(12):2272-2289. doi: 10.1002/ejhf.2029. Epub 2020 Nov 12.
5
Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease.血管紧张素转换酶抑制剂/血管紧张素II受体阻滞剂治疗及血流动力学因素与心血管疾病患者心脏中血管紧张素转换酶2的mRNA表达增加有关。
Eur J Heart Fail. 2020 Dec;22(12):2248-2257. doi: 10.1002/ejhf.2020. Epub 2020 Oct 20.
6
Cachexia, muscle wasting, and frailty in cardiovascular disease.心血管疾病中的恶病质、肌肉减少症和衰弱。
Eur J Heart Fail. 2020 Dec;22(12):2314-2326. doi: 10.1002/ejhf.2011. Epub 2020 Oct 14.
7
Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper.将姑息治疗方法融入心力衰竭治疗中：欧洲心脏病学会心力衰竭协会立场文件。
Eur J Heart Fail. 2020 Dec;22(12):2327-2339. doi: 10.1002/ejhf.1994. Epub 2020 Oct 4.
8
Heart failure in COVID-19 patients: prevalence, incidence and prognostic implications.新型冠状病毒肺炎患者的心衰：患病率、发病率和预后意义。
Eur J Heart Fail. 2020 Dec;22(12):2205-2215. doi: 10.1002/ejhf.1990. Epub 2020 Oct 7.
9
Temporal trends in decompensated heart failure and outcomes during COVID-19: a multisite report from heart failure referral centres in London.COVID-19 期间失代偿性心力衰竭的时间趋势和结局：来自伦敦心力衰竭转诊中心的多站点报告。
Eur J Heart Fail. 2020 Dec;22(12):2219-2224. doi: 10.1002/ejhf.1986. Epub 2020 Sep 28.
10
The cancer patient and cardiology.癌症患者与心脏病学。
Eur J Heart Fail. 2020 Dec;22(12):2290-2309. doi: 10.1002/ejhf.1985. Epub 2020 Oct 2.
Zotero 插件